{"id":"third-generation-fluoroquinolone","safety":{"commonSideEffects":[{"rate":"3-10%","effect":"Nausea"},{"rate":"2-8%","effect":"Diarrhea"},{"rate":"1-5%","effect":"Headache"},{"rate":"0.1-1%","effect":"Tendinopathy"},{"rate":"0.1-1%","effect":"QT prolongation"},{"rate":"1-3%","effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These agents are broad-spectrum fluoroquinolone antibiotics with enhanced activity against gram-positive bacteria and atypical pathogens compared to earlier generations. They work by binding to and inhibiting bacterial topoisomerases, enzymes essential for DNA unwinding and replication, leading to bacterial cell death. Third-generation fluoroquinolones (such as levofloxacin and moxifloxacin) have improved pharmacokinetics and tissue penetration compared to first and second-generation agents.","oneSentence":"Third-generation fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:44.850Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Acute bacterial sinusitis"},{"name":"Acute exacerbation of chronic bronchitis"},{"name":"Complicated urinary tract infections"},{"name":"Uncomplicated urinary tract infections"}]},"trialDetails":[{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT02537847","phase":"PHASE2","title":"Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2012-11","conditions":"Infection Due to Escherichia Coli, Acute Pyelonephritis","enrollment":96},{"nctId":"NCT02130713","phase":"PHASE4","title":"Treatment of Chronic Bacterial Prostatitis","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2012-01","conditions":"Chronic Bacterial Prostatitis","enrollment":210},{"nctId":"NCT00392275","phase":"PHASE4","title":"Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2002-11","conditions":"Cataract","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Third generation fluoroquinolone","genericName":"Third generation fluoroquinolone","companyName":"University of Roma La Sapienza","companyId":"university-of-roma-la-sapienza","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Third-generation fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute exacerbation of chronic bronchitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}